EAF Leads 5 Stock Surge on EPS Revisions: EAF +53%, HPP +26%
GrafTech International (EAF) surged 53.2% to $10.65 after its Q3 beat and guidance for higher Q4 pricing, while Hudson Pacific Properties (HPP) gained 26.1% on a 30.5% next-year EPS growth estimate. Granite Ridge Resources (GRNT) rose 16.1% after its EPS growth estimate was revised up 15.8 percentage points, and Genmab (GMAB) added 16.1% on positive cancer trial data.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| EAF | Industrials | 2026-10-20 | N/A | +53.2% |
| HPP | Real Estate | 2026-10-19 | N/A | +26.1% |
| GRNT | Energy | 2026-10-15 | +15.8pp | +16.1% |
| GMAB | Healthcare | 2026-10-19 | +2.4pp | +16.1% |
| DAKT | Technology | 2026-10-15 | N/A | +14.7% |
Why did EAF stock jump in October 2026?
EAF jumped 53.2% (from $6.95 to $10.65) after analysts set a 35.0% next-year EPS growth estimate on October 20 and Q3 results confirmed a pricing inflection.
The October 23 earnings release showed an adjusted loss of $1.21 per share, 17.1% better than the -$1.46 consensus, on revenue of $140.2 million that beat by 10.7%. Management guided to a mid-single-digit sequential realized price increase in Q4 and reaffirmed full-year 2026 volume and cost expectations, while also announcing the closure of its highest-cost Monterrey plant. Sequential adjusted EBITDA improved from -$22 million in Q4 2025 to $9 million in Q3 2026, the fourth straight quarter of improvement.
EAF EPS revision history → · Screener snapshot from 2026-10-20 →
FAQ: EAF
Why did EAF stock jump?
EAF jumped 53.2% to $10.65 after the October 20 EPS revision set 35.0% next-year growth and Q3 results beat estimates with guidance for higher Q4 pricing.
Is EAF a buy after the rally?
EAF trades at $10.65 after a 53.2% gain, with Q3 adjusted EBITDA of $9 million still below its interest burden, so the buy case rests on management delivering the guided Q4 price increase and 2027 recovery.
What is EAF's EPS growth estimate?
Analysts model 35.0% EPS growth next year for EAF, up from a deeply negative base as pricing inflects and costs fall.
Why did HPP stock jump in October 2026?
HPP climbed 26.1% (from $9.02 to $11.37) after the October 19 screener flagged a 30.5% next-year EPS growth estimate.
No company-specific earnings news hit the tape during the window, so the move reflects investors repricing the office REIT's recovery potential as the estimate revision signaled improving forward earnings power. The 30.5% growth rate stands out in a sector where many peers still face declining funds from operations, drawing income and value buyers to HPP's beaten-down valuation. The size of the gain shows how sensitive HPP is to estimate revisions after a prolonged office-sector downturn.
HPP EPS revision history → · Screener snapshot from 2026-10-19 →
FAQ: HPP
Why did HPP stock jump?
HPP jumped 26.1% to $11.37 after the October 19 EPS revision signaled 30.5% next-year growth, prompting investors to reprice the office REIT's recovery despite no company-specific news.
Is HPP a buy after the rally?
HPP at $11.37 has gained 26.1% since detection, and the 30.5% EPS growth estimate provides fundamental support, though office-sector risks remain a key variable.
What is HPP's EPS growth estimate?
HPP carries a 30.5% next-year EPS growth estimate, a sharp turnaround signal for the office REIT that drove the October 19 screener alert.
Why did GRNT stock jump in October 2026?
GRNT rose 16.1% (from $5.09 to $5.91) after its next-year EPS growth estimate was revised from 46.2% to 62.0% on October 15, a 15.8 percentage-point upgrade.
The revision reflects stronger expected cash flow for the oil and gas producer, likely tied to higher commodity price assumptions and efficient capital allocation in its Permian and other basins. With no company-specific news in the window, the price move tracks the estimate revision itself, as energy investors rotated toward small-cap E&P names with improving forward earnings. The 15.8-point revision is one of the largest in this screen, and the market validated it with a double-digit gain.
GRNT EPS revision history → · Screener snapshot from 2026-10-15 →
FAQ: GRNT
Why did GRNT stock jump?
GRNT jumped 16.1% to $5.91 after its next-year EPS growth estimate was revised up from 46.2% to 62.0% on October 15, a 15.8 percentage-point increase.
Is GRNT a buy after the rally?
GRNT trades at $5.91 after a 16.1% gain, with the 62.0% EPS growth estimate providing fundamental momentum, though energy price volatility remains the key risk.
What is GRNT's EPS growth estimate?
GRNT's next-year EPS growth estimate now stands at 62.0%, up from 46.2% before the October 15 revision, one of the largest upgrades in this screen.
Why did GMAB stock jump in October 2026?
GMAB jumped 16.1% (from $38.50 to $44.69) after its next-year EPS growth estimate was revised from 46.3% to 48.8% on October 19, a 2.4 percentage-point upgrade, and two positive trial readouts reinforced the thesis.
On October 23, Genmab reported Phase 3 RAINFOL-02 data showing Rina-S reduced the risk of disease progression or death by 71% in platinum-resistant ovarian cancer, sending shares up 9%. On October 26, mid-stage petosemtamab data showed a 75% response rate in first-line colorectal cancer, adding another 12-13% gain. The estimate revision and the clinical catalysts combined to drive the 16.1% total move.
GMAB EPS revision history → · Screener snapshot from 2026-10-19 →
FAQ: GMAB
Why did GMAB stock jump?
GMAB jumped 16.1% to $44.69 after an October 19 EPS estimate revision to 48.8% next-year growth, then two positive cancer trial readouts on October 23 and 26 added further gains.
Is GMAB a buy after the rally?
GMAB at $44.69 has gained 16.1%, with the 48.8% EPS growth estimate and positive RAINFOL-02 and petosemtamab data supporting the bull case, though clinical and regulatory risks remain.
What is GMAB's EPS growth estimate?
GMAB's next-year EPS growth estimate is 48.8%, up from 46.3% before the October 19 revision, reflecting confidence in its antibody-drug conjugate pipeline.
Why did DAKT stock jump in October 2026?
DAKT gained 14.7% (from $18.27 to $20.96) after the October 15 screener flagged a 28.1% next-year EPS growth estimate.
No earnings-related news surfaced in the window, so the move reflects investors positioning for the display and scoreboard maker's improving earnings outlook, likely tied to strong demand in sports venue and transportation display projects. The 28.1% growth rate signals a meaningful acceleration from prior years, and the steady price climb suggests accumulation rather than a single catalyst. DAKT's niche industrial technology exposure gives it leverage to infrastructure and venue upgrade spending cycles.
DAKT EPS revision history → · Screener snapshot from 2026-10-15 →
FAQ: DAKT
Why did DAKT stock jump?
DAKT jumped 14.7% to $20.96 after the October 15 EPS revision signaled 28.1% next-year growth, with no company-specific news driving the move.
Is DAKT a buy after the rally?
DAKT trades at $20.96 after a 14.7% gain, with the 28.1% EPS growth estimate supporting the move, though the absence of fresh news leaves the thesis dependent on execution.
What is DAKT's EPS growth estimate?
DAKT carries a 28.1% next-year EPS growth estimate, the key metric that triggered the October 15 screener detection.
Today's performers show that EPS estimate revisions remain a powerful short-term catalyst, with EAF's 53.2% gain proving that even deeply unprofitable companies can rally hard when forward estimates inflect. The mix of energy, real estate, healthcare, and technology names suggests the market is rewarding earnings momentum across sectors rather than favoring a single theme.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →